Location History:
- The Hague, NL (2019 - 2021)
- Leiden, NL (2020 - 2022)
- Den Hagg, NL (2024)
Company Filing History:
Years Active: 2019-2024
Title: Hee Lam Chan: Innovator in Oligonucleotide Therapy
Introduction
Hee Lam Chan is a prominent inventor based in Leiden, Netherlands. He has made significant contributions to the field of medicine, particularly in the development of oligonucleotide therapies. With a total of seven patents to his name, Chan is recognized for his innovative approaches to treating genetic eye diseases.
Latest Patents
One of Chan's latest patents focuses on oligonucleotide therapy for Leber congenital amaurosis. This invention involves antisense oligonucleotides that target the mutation in intron 26 of the CEP290 gene. These oligonucleotides are designed to reduce the inclusion of the aberrant exon into the CEP290 mRNA. They include no more than three consecutive guanosines, have no more than 60% guanosine nucleobases, and include at most one CpG sequence. Additionally, they do not have the potential to form a hairpin comprising three or more consecutive complementary base pairs. Another significant patent relates to antisense oligonucleotides for the treatment of eye disease. This invention pertains to novel antisense oligonucleotides (AONs) that may be used in the treatment, prevention, and/or delay of Usher syndrome type II and/or USH2A-associated non-syndromic retina degeneration.
Career Highlights
Hee Lam Chan is currently associated with Proqr Therapeutics II B.V., where he continues to advance his research and development efforts. His work has garnered attention in the medical community, particularly for its potential impact on treating genetic disorders.
Collaborations
Chan collaborates with notable colleagues, including Hester Catharina Van Diepen and Janne Juha Turunen. Their combined expertise contributes to the innovative research being conducted at Proqr Therapeutics.
Conclusion
Hee Lam Chan is a leading inventor in the field of oligonucleotide therapy, with a focus on addressing genetic eye diseases. His contributions through patents and collaborations highlight the importance of innovation in medical research.